Marcus Buggert’s group at the Centre for Infectious Medicine develops mRNA-based, CD19-directed CAR T cells for chronic lymphocytic leukaemia. The project uses electroporation and targeted lipid nanoparticles to generate transient CAR expression and examines how disease stage, treatment and T-cell differentiation affect killing of malignant B cells. Work…